Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.49 |
| ▸ | CTSL | P07711 | 5/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.40 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.40 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7138664 | 0.84 | CTSL (0.47) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL7163035 | 0.82 | CTSB (0.48) | CTSSCTSLCTSBCTSKPSMB5 | |
| SCHEMBL7132876 | 0.78 | CTSL (0.65) | CTSSCTSLCTSBCTSKMMP3 | |
| SCHEMBL7136830 | 0.77 | CTSK (0.59) | CTSSCTSLCTSBCTSKPSMB5 | |
| SCHEMBL7138074 | 0.76 | CTSL (0.44) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL7137827 | 0.76 | CTSL (0.58) | CTSSCTSLCTSBCTSKPSMB5 | |
| SCHEMBL7139836 | 0.75 | PSMB5 (0.49) | CTSSCTSLCTSBCTSKPSMB5 | |
| SCHEMBL7134280 | 0.73 | CTSB (0.46) | CTSSCTSLCTSBCTSKITGB3 | |
| SCHEMBL7133702 | 0.73 | CTSL (0.70) | CTSSCTSLCTSK | |
| SCHEMBL7133755 | 0.73 | CTSC (0.54) | PSMB5GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | disclosed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | CTSS 9/4885CTSL 14/4885CTSB 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.